Skip to main content

Table 1 Characteristics of the GALA II study participants recruited between 2006 and 2014 that were included in the EWAS of lung function

From: Epigenome-wide association study of lung function in Latino children and youth with asthma

Characteristic

EPIC

450 K

Puerto Rican

Mexican American

Puerto Rican

Mexican American

Sample size

160

42

90

106

Age (y)

13.3 ± 3.0

14.4 ± 3.8

12.0 ± 2.9

12.7 ± 3.8

Female n (%)

72 (45.0)

20 (47.6)

37 (41.1)†

63 (59.4)†

Height (cm)

154.3 ± 13.7

156.0 ± 14.4

150.2 ± 14.8

149.3 ± 14.7

Weight (Kg)

56.6 ± 20.3

63.8 ± 23.7

50.9 ± 23.6

57.5 ± 27.6

Body Mass Index (BMI) category, n (%)

*

   

Underweight

3 (1.9)

0 (0)

7 (7.8)†

3 (2.8)†

Normal

81 (50.9)

15 (35.7)

52 (57.7)†

44 (41.5)†

Overweight

30 (18.9)

9 (21.4)

7 (7.8)†

14 (13.2)†

Obese

45 (28.3)

18 (42.9)

24 (26.7)†

45 (42.5)†

Pre-FEV1 (L)

2.4 (0.7)†

2.9 (0.9)†

2.3 (0.7)

2.5 (0.8)

Pre-FEV1% predicted

88.5 (14.7)†

98.9 (14.0)†

91.5 (12.8)†

99.2 (12.8)†

Pre-FVC (L)

2.8 (0.9)†

3.5 (1.2)†

2.7 (0.9)†

3.0 (1.0)†

Pre-FVC % predicted

90.2 (15.1)†

103.4 (13.8)†

93.7 (12.9)†

103.1 (12.6)†

Pre-FEV1/FVC (L)

0.86 (0.08)

0.84 (0.07)

0.86 (0.07)

0.85 (0.07)

Pre-FEV1/FVC % predicted

98.2 (8.9)†

96.0 (7.1)†

97.8(7.7)

96.4 (7.9)

Post-FEV1 (L)

2.7 (0.8)†

3.13 (0.9)†

2.5 (0.8)

2.65 (0.8)

Post-FEV1% predicted

98.1 (15.5)†

104.6 (12.3)†

99.8 (12.4)†

104.9 (12.5)†

Post-FVC (L)

3.0 (0.9)†

3.5 (1.0)†

2.9 (0.9)

3.0 (1.0)

Post-FVC % predicted

97.3 (15.8)†

105.1 (12.7)†

99.0 (13.8)†

105 (13.1)†

Post-FEV1/FVC (L)

0.88 (0.06)

0.87 (0.07)

0.88 (0.06)

0.88 (0.06)

Post-FEV1/FVC % predicted

100.6 (7.2)†

98.8 (6.3)†

100.9 (5.9)

100.3 (6.4)

In utero maternal smoking, n (%)

9 (5.7)

1 (2.4)

30 (33.3)†

13 (12.3)†

SHS, n (%)

30 (19.7)**

5 (11.9)

24 (26.7)

27 (26.7)**

Controller medication last 2 weeks, n (%)

34 (21.3)

13 (31.0)

25 (27.8)

39 (36.8)

Maternal high-school education, n (%)

139 (86.9)†

25 (59.5)†

68 (76.4)***†

67 (63.2)†

Insurance status, n (%)

†

****†

†

****†

Government

99 (61.9)

24 (60.0)

68 (75.6)

70 (66.7)

Private

57 (35.6)

10 (25.0)

22 (24.4)

28 (26.7)

None

4 (2.5)

6 (15.0)

0 (0)

7 (6.6)

Preterm birth (< 37 weeks), n (%)

56 (35.2)*****

12 (29.3)*****

30 (33.3)

26 (25.7)*****

  1. †P value < 0.05 for the comparison of Mexicans and Puerto Ricans profiled with the same array
  2. 450K: Illumina Infinium HumanMethylation450 BeadChip 450K array; EPIC: Illumina Infinium MethylationEPIC array; FEV1: forced expiratory volume in 1 s; FVC: Forced vital capacity; Post: Post-administration of albuterol; Pre: Pre-administration of albuterol
  3. *BMI was available for 159 Puerto Ricans profiled with the EPIC array. **SHS was available for 152 Puerto Ricans profiled with the EPIC array and 101 Mexicans profiled with the 450K array. ***Maternal education level was available for 89 Puerto Ricans profiled with the 450K array. ****Insurance status was available for 40 and 105 Mexicans profiled with the EPIC and 450K array, respectively. *****Preterm birth data was available for 159 Puerto Ricans and 41 Mexicans profiled with the EPIC array and 101 Mexicans profiled with the 450K array
  4. For continuous variables, the mean and standard deviation are displayed, and the Mann–Whitney Wilcoxon test was applied for the comparison of cases versus controls. For categorical variables, the number and proportion of subjects in each category are shown and a χ2 test was applied for the comparison of cases versus controls
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us